Biosimilars and Generic Entry — How Much Can You Actually Save?

It depends entirely on the molecule, and only one has a domestic biosimilar today. For nivolumab, a domestically manufactured biosimilar was launched in January 2026 at roughly a quarter of the reference product's price. For pembrolizumab there is no Indian biosimilar as of August 2026. All figures here are indicative, as of August 2026.

Immunotherapy is not one market with one price trend. Each molecule has its own patent clock. Indian patent protection for nivolumab lapsed in 2026, which opened the door to domestic manufacture. Pembrolizumab's protection begins lapsing only around 2028-29, so no equivalent saving exists for it today — whatever a reseller may tell you.

Prices are set by manufacturers and distributors, not by CION, and they move. Ask your treating team for the current itemised figure in writing before you commit.

Only the drug line. It is the largest single line, so the saving is real and worth chasing. But administration, monitoring blood tests, response-assessment scans and the management of any side effect are billed exactly the same either way. Plan against the whole bill, not the vial price.

A large cut to the biggest line, no change to the rest. Plan around the total, not the vial price.

Regulators do not approve a biosimilar unless comparative data show no clinically meaningful difference from the reference product in quality, efficacy, safety and immunogenicity. In India that judgement is made by CDSCO under its similar-biologics pathway. A biosimilar is highly similar, not chemically identical — no biologic is identical, including the originator's own batches.

The word people search for is "generic", and that is where the confusion starts. A generic is an identical chemical copy of a small-molecule tablet, cleared on bioequivalence data alone. Checkpoint inhibitors are antibodies grown in living cells, so the bar is higher. That is why a "generic immunotherapy" is not a category that exists in India.

Approval is granted for specific indications. Whether an approved biosimilar suits your cancer type stays a clinical decision for your oncologist and the tumour board.

Counterfeit checkpoint inhibitors have been reported entering the Indian market ahead of patent expiry. Verification is therefore a safety step, not bureaucracy. Confirm CDSCO approval, buy only through the hospital pharmacy or its authorised distributor, match batch numbers between vial and carton, and confirm the cold chain was never broken.

1. 1

   Confirm current CDSCO marketing approval

   For that exact product, not just the molecule. An approved molecule does not make every vial of it legitimate.

2. 2

   Buy only through the hospital pharmacy or its authorised distributor

   Never a reseller, agent or online listing, however much cheaper the offer sounds.

3. 3

   Match the vial to the carton

   Batch number, manufacturing date and expiry identical on both, printed cleanly, and recorded in your file.

4. 4

   Confirm an unbroken cold chain

   These products are stored at 2-8°C and must never be frozen. Refuse a vial that has been out of range.

5. 5

   Ask to see the sealed vial at the chairside

   Before it is reconstituted, with its invoice. A refusal is itself information.

Switching product is one lever, and it only exists for one molecule today. Scheme cover, a correctly filed insurance pre-authorisation, an itemised written estimate before you start, and honest conversations about duration usually move the number more than the search for a cheaper vial does.

• Check scheme cover first. Under Telangana's Aarogyasri scheme, certain immunotherapy packages may be covered up to scheme-defined ceilings. Empanelment and ceilings change — confirm the current position with the hospital's scheme desk. See Is Immunotherapy Covered Under Aarogyasri?
• Get the insurance pre-authorisation right first time. Many refusals are documentation problems, not policy exclusions — how insurers treat immunotherapy and why claims get rejected.
• Ask for an itemised estimate before the first cycle. Drug, day care, monitoring and scans listed separately, not one lump figure.
• Understand what drives duration. Interval and total duration are clinical decisions made on response and tolerance, never a quiet budget adjustment.
• Ask the pharmacy about manufacturer assistance programmes. Terms change often, and they can be withdrawn once a lower-cost version arrives.
• Ask whether any clinical trial fits your diagnosis. Trials sometimes supply treatment at no drug cost. Eligibility is strict and enrolment is never promised.
• Confirm day care versus admission. Immunotherapy is given as day care at CION centres; an admission bills differently.

Five questions settle almost everything. Which exact product, is it CDSCO-approved, what is the indicative total for a year, how many cycles before the first assessment, and what the honest alternative is if the family cannot sustain it. Ask them together, and ask for the answers in writing.

• "Which exact product, and is it CDSCO-approved?" Name, manufacturer, approval status — this closes off most counterfeit risk.
• "Is a biosimilar available for this molecule in India today?" If not, a cheaper version offered elsewhere is a warning sign.
• "What is the indicative total for a year, itemised?" Drug, day care, monitoring and scans separately, and dated.
• "How many cycles before we know whether this is working?" Knowing the first decision point lets a family plan in stages.
• "If we cannot sustain this, what is the honest alternative?" There is usually more than one reasonable path, including not starting.

Funding from abroad? Ask for the itemised estimate in Indian rupees, dated, and ask what is excluded — scans, admissions and side-effect management usually are. A lower drug price does not change the number of cycles.

A lower drug price is one part of what your family will actually pay. These companion pages cover the other three levers.

• Is Immunotherapy Covered Under Aarogyasri? — how scheme packages and ceilings work.
• Does Health Insurance Cover Immunotherapy in India? — what private policies pay for, and where the gaps sit.
• Why Immunotherapy Insurance Claims Get Rejected — the avoidable documentation errors behind most refusals.
• Immunotherapy at CION Cancer Clinics — eligibility review, day-care treatment and cost counselling as one pathway.

Decisions for Healing, Not Billing

We put the numbers in front of you first, including the option of not starting, so the decision stays yours to make.